Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 15;7(1):e001209.
doi: 10.1136/openhrt-2019-001209. eCollection 2020.

Surgical Complexity and Outcome of Patients Undergoing Re-do Aortic Valve Surgery

Renata Greco  1 , Mirko Muretti  1 , Jasmina Djordjevic  1 , Xu Yu Jin  2   3 , Elaine Hill  4 , Maurizio Renna  4 , Mario Petrou  5
Affiliations

Surgical Complexity and Outcome of Patients Undergoing Re-do Aortic Valve Surgery

Renata Greco et al. Open Heart. .

Abstract

Objectives: Re-do aortic valve surgery carries a higher mortality and morbidity compared with first time aortic valve replacement (AVR) and often requires concomitant complex procedures. Transcatheter aortic valve replacement (TAVR) is an option for selective patients. The aim of this study is to present our experience with re-do aortic valve procedures and give an insight into the characteristics of these patients and their outcomes.

Methods: Retrospective review of 80 consecutive re-do aortic valve procedures.

Results: Mean patients' age was 51.80±18.73 years. Aortic regurgitation (AR) was present in 51 (65.4%) patients and aortic stenosis (AS) in 38 (48.7%). Indications for reoperation were: infective endocarditis (IE) (23.8%), bioprosthetic degeneration (12.5%), mechanical valve dysfunction (5%), paravalvular leak (6.2%), patient-prosthesis mismatch (3.8%), native valve disease (25%), aortic aneurysm, pseudoaneurysm and dissection (35%), aortic root/homograft degeneration (27.5%). Forty-one (51.2%) patients underwent re-do AVR, 39 (48.8%) re-do complex aortic valve surgery (28 root, 23 ascending aorta and 6 hemiarch procedures) and 37.5% concomitant procedures. A bioprosthesis was implanted in 43.8%, a mechanical valve in 37.5%, a composite graft in 2.5%, a Biovalsalva graft in 6.2% and a homograft in 10% of patients. In-hospital mortality was 3.8% and incidence of major complications was low.

Conclusions: A significant proportion of patients were young (61%<60 y), required complex aortic procedures (49%) or presented with contraindications for TAVR (mechanical valve, AR, IE, proximal aortic disease, need for concomitant surgery). Re-do aortic surgery remains the only treatment for such challenging cases and can be performed with acceptable mortality and morbidity in a specialised aortic centre.

Keywords: Trans-catheter aortic valve replacement (TAVR); aortic surgery; aortic valve replacement (AVR); re-do surgery.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Launcelott S, Ouzounian M, Buth KJ, et al. . Predicting in-hospital mortality after Redo cardiac operations: development of a preoperative Scorecard. Ann Thorac Surg 2012;94:778–84. 10.1016/j.athoracsur.2012.04.062 - DOI - PubMed
    1. Kaneko T, Vassileva CM, Englum B, et al. . Contemporary outcomes of repeat aortic valve replacement: a benchmark for transcatheter Valve-in-Valve procedures. Ann Thorac Surg 2015;100:1298–304. 10.1016/j.athoracsur.2015.04.062 - DOI - PubMed
    1. Onorati F, Biancari F, De Feo M, et al. . Mid-Term results of aortic valve surgery in redo scenarios in the current practice: results from the multicentre European record (REdo cardiac operation research database) initiative†. Eur J Cardiothorac Surg 2015;47:269–80. 10.1093/ejcts/ezu116 - DOI - PubMed
    1. Ohira S, Miyata H, Doi K, et al. . Risk model of aortic valve replacement after cardiovascular surgery based on a national Japanese database. Eur J Cardiothoracic Surg 2017;51:347–53. - PubMed
    1. Baumgartner H, Falk V, Bax JJ, et al. . ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 2017;2017:2739–91. - PubMed

MeSH terms